The effect of lupus disease on the pregnant women and embryos: a retrospective study from 2010 to 2014
Background and aims
Pregnancy in women with systemic lupus erythematosus (SLE) is one of the challenges of recent studies. Women should prevent the onset of relapses with medications before and after pregnancy, and on the other hand, the effect of these medicines considers the health and development of the fetus. In this retrospective study, the effects of anti-phospholipid syndrome and the use of common drugs such as methotrexate, cyclosporine, and azathioprine and their side effects on maternal health and ultimately the development of the fetus have been investigated.
Material and methods
This study is a descriptive and retrospective epidemiologic study that was conducted in 2016 to investigate maternal and fetal complications in SLE patients. We prepared forms of data recording, including age, occupation, and other important information and then analyzed them in SPSS version 22.
The results showed that the presence of anti-phospholipid syndrome in pregnant women can lead to abnormalities such as preterm, IUGR, abortion, and fetal death (P value 0.0001). It also leads to complications such as nephritis, arthritis, and preeclampsia in the mother (P value 0.003). This study suggests that methotrexate and cyclosporine medications could cause fetal developmental disorders. The P value of cyclosporine was 0.0001 and the P value of methotrexate was 0.001.
• Anti-phospholipid syndrome can disrupt the development of the embryo in women with SLE who intend to become pregnant.
• Methotrexate and cyclosporine consumption before and during pregnancy can affect fetal growth.
• 7 to 33% of patients whose disease had been suppressed and controlled 6 months before pregnancy seams to relapse during the pregnancy.
• Taking medications to control the disease during pregnancy plays an important role in the progression of pregnancy and fetus health.
KeywordsAnti-phospholipid syndrome Cyclosporine Fetus complications Methotrexate Pregnancy Systemic lupus erythematous
All authors contributed equally to this work.
This study was supported by the Student Research Committee of Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Compliance with ethical standards
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
- 1.Mowla K, Rajaei E, Jalali MT, Zayeri ZD (2018) Threatening biomarkers in lupus pregnancy: biochemistry and genetic challenges. Front Biol:1–8Google Scholar
- 2.Petri M (1994) Systemic lupus erythematosus and pregnancy. Rheum Dis Clin N Am 20(1):87–118Google Scholar
- 7.Boumpas DT, Fessler BJ, Austin HA III, Balow JE, Klippel JH, Lockshin MD (1995) Systemic lupus erythematosus: emerging concepts: part 2: dermatologic and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality, and pathogenesis. Ann Intern Med 123(1):42–53CrossRefGoogle Scholar
- 9.Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, Nussenblatt RB, Stiehm ER, Tessler H, Van Gelder RN (2000) Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 130(4):492–513CrossRefGoogle Scholar
- 16.Clowse ME, Magder LS, Petri M (2011) The clinical utility of measuring complement and anti-dsDNA antibodies during pregnancy in patients with systemic lupus erythematosus. The Journal of rheumatology:jrheum 100746Google Scholar
- 19.Leroux M, Desveaux C, Parcevaux M, Julliac B, Gouyon J-B, Dallay D, Pellegrin J, Boukerrou M, Blanco P, Lazaro E (2015) Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: a descriptive cohort study. Lupus 24(13):1384–1391CrossRefGoogle Scholar
- 21.Ponticelli C, Moroni G (2015) Immunosuppression in pregnant women with systemic lupus erythematosus. Taylor & Francis, Immunosuppression in pregnant women with systemic lupus erythematosus,Google Scholar
- 22.Weber-Schoendorfer C, Chambers C, Wacker E, Beghin D, Bernard N, Centers NFP, Shechtman S, Johnson D, Cuppers-Maarschalkerweerd B, Pistelli A (2014) Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study. Arthritis Rheum 66(5):1101–1110CrossRefGoogle Scholar